<DOC>
	<DOC>NCT01791374</DOC>
	<brief_summary>This is an open label phase 1/1b study of Rilotumumab in Japanese subjects with advanced solid tumors or metastatic gastric esphagogastric (GEJ) adenocarcinoma.</brief_summary>
	<brief_title>Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Key Japanese subjects with pathologically confirmed unresectable locally advanced or metastatic carcinoma which is refractory to standard therapies or for which there is no standard therapy (Part 1 only) Japanese subjects with pathologically confirmed METpositive (fulfilling the MET IHC criteria as defined by validated IVD [in vitro diagnostic]) unresectable locally advanced or metastatic gastric or GEJ adenocarcinoma (Part 2 only) Eastern Cooperative Oncology Group (ECOG) Performance Status (0 or 1) Availability of archival tumor tissue (Part 2 only) Evaluable (measurable or nonmeasurable) disease by RECIST 1.1 criteria Able to tolerate infusions and take oral medications (Part 2 only) Key Previous systemic therapy (including chemotherapy, biologic, immunotherapy, or investigational therapy) for locally advanced or metstatic gastric or GEJ adenocarcinoma (Part 2 only) Less than 6 months have elapsed from completion of prior neoadjuvant or adjuvant chemotherapy or chemotherapy to enrollment (Part 2 only) Squamos cell history (Part 2 only) Known HER2overexpressing unresectable locally advanced or metastatic gastric or GEJ adenocarcinoma (Part 2 only) Resectable disease or suitable for definitive chemoradiation Subjects who have persistent gastric outlet obstruction, complete dysphagia or are dependent upon jejunostomy for feeding (Part 2 only) Known central nervous system metastases</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Advanced or Metastatic Gastric Cancer</keyword>
	<keyword>Advanced or Metastatic GEJ</keyword>
	<keyword>Gastric Cancer</keyword>
</DOC>